Search clinical trials for: RECIST

Total 58 results

NextPoint Therapeutics, Inc.

Recruiting

A Study of NPX887 for Participants With Solid Tumors Known to Express HHLA2/B7-H7

Metastatic Malignant Neoplasm

United States
Xueqin Yang

Recruiting

RecistTM Criteria in Evaluating the Efficacy of Targeted Therapy for NSCLC

NSCLC | Targeted Therapy | Evaluation

China
NextPoint Therapeutics, Inc.

Recruiting

A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7

Metastatic Malignant Neoplasm

United States
Masonic Cancer Center, University of Minnesota

Recruiting

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

Acute Myeloid Leukemia | Juvenile Myelomonocytic Leukemia | Acute Lymphoblastic Leukemia | AML | Acute Leukemia | Neurofibromatosis 1 | Hematologic Malignancy | Myelodysplasia | Minimal Residual Disease | Chromosome Abnormality | Monosomy 7 | Remission | Somatic Mutation | Cytogenetic Abnormality | TP53 | Fetal Hemoglobin | Intrachromosomal Amplification of Chromosome... and other conditions

United States
OncoRadiomics
University Hospital, Antwerp

Not yet recruiting

Artificial Intelligence for Help Non-Small Cell Lung Cancer: Measure Cancer Biology and Treatment Response Via Imaging (SALMON)

Non Small Cell Lung Cancer
Centre Leon Berard
Novartis; National Cancer Institute, France

Recruiting

HDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic Soft Tissue Sarcomas (AMPHISARC)

Advanced Soft-tissue Sarcoma | Metastatic Soft-tissue Sarcoma

France
Sheba Medical Center
Bristol-Myers Squibb

Recruiting

Maintenance Ipilimumab + Nivolumab Post Induction Chemotherapy + SBRT for First Line Treatment Stage IV Pancreatic Cancer

Stage IV Pancreatic Cancer

Israel
Health Science Center of Xi'an Jiaotong University

Recruiting

Efficacy and Safety of Involving Field Radiotherapy in the Oligo-lesions(Metastasis/Recurrent/Refractory) of Ovarian Cancer

Ovarian Cancer | Cancer of the Ovary | Ovarian Neoplasm | Ovary Cancer | Neoplasms, Ovarian | Ovary Neoplasms | Ovary Neoplasm | Cancer of Ovary | Cancer, Ovarian | Ovarian Cancers | Neoplasm, Ovarian | Neoplasm, Ovary | Neoplasms, Ovary | Cancer, Ovarian Stromal | Cancers, Ovary | Ovary Cancers | Cancers, Ovarian

China
Sheba Medical Center
Rambam Health Care Campus; AstraZeneca; Tel-Aviv Sourasky Medical Center

Recruiting

Concomitant Radiotherapy, Tremelimumab & Durvalumab for Advanced NSCLC Patients Progressing on First-line Immunotherapy (CORAL-Lung)

Metastatic or Locally Advanced NSCLC

Israel
Institut Curie

Recruiting

LIquid Biopsy to prEdict Responses To First-line immunotherapY in Metastatic Non-small Cell LUNG Cancer. LIBERTY LUNG (LIBERTYLUNG)

NSCLC Patient in a Metastatic Stage Eligible for First-line Treatment With Immune Checkpoint Inhibitor

France
Xynomic Pharmaceuticals, Inc.

Recruiting

A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)

Renal Cell Carcinoma

China, Spain, United States, Italy, Korea, Republic of, Poland
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Active, not recruiting

Bintrafusp Alfa Program Rollover Study

Cancer | Lung Cancer

Korea, Republic of, Spain, Germany, Japan, Taiwan, China, Italy, United States, Belgium, Russian Federation, Turkey, Ukraine
Bristol-Myers Squibb

Terminated

A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (CheckMate 7G8)

Urinary Bladder Neoplasms

United States, Netherlands, Italy, Argentina, Australia, Austria, Brazil, Canada, Chile, France, Germany, Greece, Israel, Japan, Russian Federation, Spain, Sweden
Cytovation AS
Merck Sharp & Dohme LLC

Active, not recruiting

A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers (Catalyst)

Advanced Breast Cancer | Advanced Melanoma | Advanced Head and Neck Squamous Cell Carcinoma

United States, France, Italy, Spain, Netherlands
Melanoma Institute Australia
Merck Sharp & Dohme LLC

Active, not recruiting

A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III Melanoma (Neo PeLe)

Melanoma Stage III

Australia
Dan Zandberg
Bristol-Myers Squibb

Active, not recruiting

Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy

Squamous Cell Carcinoma of the Head and Neck

United States
University Hospital Southampton NHS Foundation...
British Lung Foundation; University of Southampton

Active, not recruiting

Niraparib Efficacy in Patient With Unresectable Mesothelioma (NERO)

Mesothelioma, Malignant

United Kingdom
The Netherlands Cancer Institute
4SC

Active, not recruiting

Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma (DONIMI)

Malignant Melanoma Stage III

Netherlands
Melanoma Institute Australia
Merck Sharp & Dohme LLC; Novartis

Active, not recruiting

Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma (Neo Trio)

Melanoma

Australia
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monotherapy in Advanced Renal Cell Cancer

Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1

China
Median Technologies

Completed

BICR in New Therapeutic Lung Cancer Trials

Lung Cancer

France
University of Southampton
Bristol-Myers Squibb

Active, not recruiting

CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma (CONFIRM)

Mesothelioma

United Kingdom
ERYtech Pharma

Completed

Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC (Trybeca-1)

Pancreatic Adenocarcinoma

United States, United Kingdom, France
The Netherlands Cancer Institute
Genentech, Inc.; EurocanPlatform; Rather

Completed

Clinical Trial to Evaluate the Safety and Effectiveness of GDC-0032 When Given Alongside Tamoxifen (Poseidon)

Breast Cancer

Spain, Netherlands, France, United Kingdom
Mayo Clinic

Terminated

Use of Adipose Derived Regenerative Cells in Bilateral Femoral Head Osteonecrosis

Osteonecrosis

United States
Egas Moniz - Cooperativa de Ensino Superior, CRL

Completed

Effect of Aqueous Cinnamon Extract on the Postprandial Glycaemia Levels in Type 2 Diabetes Mellitus

Type 2 Diabetes
El Kendi Pharmaceuticals Manufacturing Company

Completed

Evaluate Efficacy of the Association Nimotuzumab(HR3) /Cisplatin-Vinorelbine on Patients With Cervical Carcinom (CIMAHOPE)

Cervical Cancer

Algeria
NuGenerex Immuno-Oncology
Merck Sharp & Dohme LLC; NSABP Foundation Inc

Active, not recruiting

Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast Cancer (NSABP FB-14)

Triple-negative Breast Cancer

United States
Cem Ilgin Erol

Completed

Comparison of MRI With PET / CT in the Evaluation of Response to Neoadjuvant Therapy Based on the Molecular Subtypes of Breast Cancer

Breast Cancer | Chemotherapy Effect

Turkey
Bayer

Completed

Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)

Carcinoma, Hepatocellular

Belgium, China, Hong Kong, Switzerland, Japan, France, Spain, Germany, United States, Austria, Czechia, United Kingdom, Korea, Republic of, Thailand, New Zealand, Hungary, Israel, Italy, Taiwan, Singapore, Turkey
Bayer

Completed

Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)

Carcinoma, Hepatocellular

Belgium, France, Switzerland, Germany, United States, Austria, New Zealand, Hungary, Korea, Republic of, Italy, Hong Kong, Thailand, Spain, Taiwan, Japan, Czechia, United Kingdom
Brno University Hospital
Masaryk University; Masaryk Memorial Cancer Institute

Completed

Volumetric Analysis of Hepatocellular Carcinoma After Transarterial Chemoembolization

Hepatocellular Carcinoma | Hepatocellular Carcinoma by BCLC Stage
Novartis Pharmaceuticals

Completed

Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function

Hepatic Impairment | Solid Tumors

Belgium, Germany, Netherlands, Italy, Singapore, United States
AIO-Studien-gGmbH
Novartis Pharmaceuticals; Assign Data Management and Biostatistics GmbH

Completed

Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study (EVINEC)

Neuroendocrine Carcinoma, Grade 3 | Poorly Differentiated Malignant Neuroendocrine Carcinoma | Neuroendocrine Carcinoma, Grade 1 [Well-differentiated Neuroendocrine Carcinoma] That Switched to G3 | Neuroendocrine Carcinoma, Grade 2 [Moderately Differentiated Neuroendocrine Carcinoma]... and other conditions

Germany
Seoul National University Hospital

Unknown

Role of Perfusion CT in Pancreatic Cancer

Neuroendocrine Carcinoma of Pancreas | Adenocarcinoma, Pancreas

Korea, Republic of
Hospices Civils de Lyon

Completed

Therapeutic Drug Monitoring of Antifungals in Intensive Care Units (Fungi-up)

Intensive Care Unit Patients

France
GlaxoSmithKline
Parexel

Terminated

First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors

Neoplasms, Pancreatic

United States
Nilogen Oncosystems
Henry Ford Health System

Unknown

Pilot Study of Nilogen 3D-EX and Its Ability to Predict Therapeutic Response to Anti-PD1 or Anti-PDL1 in NSCLC (NO3DEXPL)

Non Small Cell Lung Cancer

United States
Grupo Espanol de Tumores Neuroendocrinos

Completed

Radiological Response of Pancreatic Neuroendocrine Tumors: Comparison Between the Choi and the RECIST Criteria (CRIPNET)

Pancreatic Neuroendocrine Tumors

Spain
Johnson & Johnson Medical, China

Completed

China CellSearch Study

Metastatic Breast Cancer | Benign Breast Disease

China
AbbVie

Completed

Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

United States
Institut Paoli-Calmettes
Société Francophone d'Onco-Gériatrie

Unknown

Elderly Cancer PatIents, Safety and qualiTy of Life Under immunOtheraPies (EPITOP-01)

Advanced or Metastatic NSCLC | Advanced or Metastatic Melanoma

France
GERCOR - Multidisciplinary Oncology Cooperative...

Completed

Evaluation of Treatment Response With CHOI and RECIST Criteria and CT Texture Analysis in Patients With Metastatic Colorectal Cancer Treated With Regorafenib (TEXCAN)

Metastatic Colorectal Cancer

France
Peking University People's Hospital
Xijing Hospital; Second Affiliated Hospital, School of Medicine, Zhejiang University

Unknown

Clinical Evaluation for Sarcoma Originated From Bone (CESOFB)

Survival | Sensitivity | Specificity | Histological Response

China
Astellas Pharma Inc
Medivation LLC, a wholly owned subsidiary of Pfizer Inc.

Completed

A Study of MDV3100 to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of in Prostate Cancer Patients

Prostate Cancer | Prostate Neoplasms | Castration Resistant Prostate Cancer (CRPC)

Japan
Fondazione Policlinico Universitario Agostino Gemelli...

Completed

Beta-Glucan Driven vs. Empirical Antifungal Therapy in Critically Ill Patients

Antifungal Agents

Italy
Millennium Pharmaceuticals, Inc.

Completed

Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer

Fallopian Tube Cancer | Breast Carcinoma | Ovarian Carcinoma | Peritoneal Cancer

United States
Vivolux AB
Theradex

Terminated

Study of Safety and Tolerability of VLX600, an Iron Chelator, in Patients With Refractory Advanced Solid Tumors

Refractory Cancer

United States
Grupo Espanol Multidisciplinario del Cancer Digestivo

Completed

Correlation Between RECIST, Morphologic Response by CT- Histopathologic Response in Hepatic Metastasis Secondary to Colorectal Cancer (AVAMET)

Colorectal Cancer | Hepatic Metastasis

Spain
Radboud University Medical Center

Terminated

Efficacy of Hyperbaric Oxygen Therapy in the Treatment of Osteoradionecrosis

Osteoradionecrosis

Netherlands

Search clinical trials for: RECIST

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovakia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations